EARNEST Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

EARNEST Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-111	Closed	-$38.6K	–	1069
2023 Q3	$38.6K	Hold	111	–	–	﹤0.01%	393
2023 Q2	$39.1K	Hold	111	–	–	﹤0.01%	373
2023 Q1	$35K	Hold	111	–	–	﹤0.01%	379
2022 Q4	$32.1K	Hold	111	–	–	﹤0.01%	393
2022 Q3	$32K	Hold	111	–	–	﹤0.01%	378
2022 Q2	$31K	Hold	111	–	–	﹤0.01%	389
2022 Q1	$29K	Hold	111	–	–	﹤0.01%	414
2021 Q4	$24K	Hold	111	–	–	﹤0.01%	458
2021 Q3	$20K	Hold	111	–	–	﹤0.01%	488
2021 Q2	$22K	Hold	111	–	–	﹤0.01%	462
2021 Q1	$24K	Hold	111	–	–	﹤0.01%	432
2020 Q4	$26K	Hold	111	–	–	﹤0.01%	401
2020 Q3	$30K	Hold	111	–	–	﹤0.01%	349
2020 Q2	$32K	Hold	111	–	–	﹤0.01%	334
2020 Q1	$26K	Hold	111	–	–	﹤0.01%	354
2019 Q4	$24K	Hold	111	–	–	﹤0.01%	407
2019 Q3	$19K	Hold	111	–	–	﹤0.01%	456
2019 Q2	$20K	Hold	111	–	–	﹤0.01%	449
2019 Q1	$20K	Hold	111	–	–	﹤0.01%	443
2018 Q4	$18K	Hold	111	–	–	﹤0.01%	439
2018 Q3	$21K	Hold	111	–	–	﹤0.01%	428
2018 Q2	$19K	Hold	111	–	–	﹤0.01%	445
2018 Q1	$18K	Hold	111	–	–	﹤0.01%	451
2017 Q4	$17K	Buy	+111	New	+$16.4K	﹤0.01%	454
2017 Q1	–	Sell	-111	Closed	-$8K	–	886
2016 Q4	$8K	Buy	+111	New	+$9.03K	﹤0.01%	576

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

EARNEST Partners's VRTX Position: Q4 2023 in Review

EARNEST Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 111 shares — an estimated $38.6K sold.

EARNEST Partners first reported a position in VRTX in Q4 2016 and held it in 25 quarters. The position peaked at $39.1K in Q2 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

EARNEST Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 111 Vertex Pharmaceuticals shares in Q4 2023, an estimated $38.6K.
EARNEST Partners first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 25 quarters.
EARNEST Partners's Vertex Pharmaceuticals position peaked at $39.1K in Q2 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.